Dyskinesia
14
1
1
12
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
50%
7 trials in Phase 3/4
58%
7 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (14)
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
Registry and Natural History of Epilepsy-Dyskinesia Syndromes
Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia
A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients
Famotidine for Levodopa-induced Dyskinesia in PD
Capturing Parkinson's Disease Medication Side Effects During Daily Activities
Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia